Clinical Trial Update: Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating chemotherapy combined with immune checkpoint inhibitors in ALK-rearranged non-small cell lung cancer patients who previ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED